# Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

> **NCT07643623** · PHASE2,PHASE3 · RECRUITING · sponsor: **Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.** · enrollment: 720 (estimated)

## Conditions studied

- Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** tegafur, Gimeracil and Oteracil Potassium Capsules
- **DRUG:** Sintilimab Placebo
- **DRUG:** Sintilimab
- **DRUG:** Ipilimumab N01
- **DRUG:** Oxaliplatin for injection
- **DRUG:** Ipilimumab N01 Placebo

## Key facts

- **NCT ID:** NCT07643623
- **Lead sponsor:** Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2031-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 720 (ESTIMATED)
- **Last updated:** 2026-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643623, "Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07643623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*